WO2013023043A3 - Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy - Google Patents

Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy Download PDF

Info

Publication number
WO2013023043A3
WO2013023043A3 PCT/US2012/050124 US2012050124W WO2013023043A3 WO 2013023043 A3 WO2013023043 A3 WO 2013023043A3 US 2012050124 W US2012050124 W US 2012050124W WO 2013023043 A3 WO2013023043 A3 WO 2013023043A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid tumors
erbb3
treatment
immunotherapy
combination
Prior art date
Application number
PCT/US2012/050124
Other languages
French (fr)
Other versions
WO2013023043A2 (en
Inventor
Victor Moyo
Joseph Pearlberg
Isabelle TABAH-FISCH
Original Assignee
Merrimack Pharmaceuticals, Inc.
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals, Inc., Sanofi filed Critical Merrimack Pharmaceuticals, Inc.
Priority to AU2012294326A priority Critical patent/AU2012294326A1/en
Publication of WO2013023043A2 publication Critical patent/WO2013023043A2/en
Publication of WO2013023043A3 publication Critical patent/WO2013023043A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

Provided are methods and compositions for clinical treatment of solid tumors (e.g., advanced solid tumors) using anti-ErbB3 antibodies combined with a second agent selected from the group consisting of gemcitabine, carboplatin, pemetrexed, and cabazitaxel. Also provided are methods and compositions for clinical treatment of solid tumors using anti-ErbB3 antibodies combined with cetuximab and irinotecan.
PCT/US2012/050124 2011-08-10 2012-08-09 Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy WO2013023043A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012294326A AU2012294326A1 (en) 2011-08-10 2012-08-09 Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201161522063P 2011-08-10 2011-08-10
US61/522,063 2011-08-10
US201161530935P 2011-09-02 2011-09-02
US61/530,935 2011-09-02
US201161535303P 2011-09-15 2011-09-15
US61/535,303 2011-09-15
US201261616902P 2012-03-28 2012-03-28
US61/616,902 2012-03-28
US201261638611P 2012-04-26 2012-04-26
US61/638,611 2012-04-26
FR1255209 2012-06-05
FR1255209 2012-06-05
FR1256174 2012-06-28
FR1256174 2012-06-28

Publications (2)

Publication Number Publication Date
WO2013023043A2 WO2013023043A2 (en) 2013-02-14
WO2013023043A3 true WO2013023043A3 (en) 2013-04-18

Family

ID=47669228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/050124 WO2013023043A2 (en) 2011-08-10 2012-08-09 Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy

Country Status (2)

Country Link
AU (1) AU2012294326A1 (en)
WO (1) WO2013023043A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2544680T3 (en) * 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
CN104159924B (en) * 2011-12-05 2018-03-16 诺华股份有限公司 The antibody of EGF-R ELISA 3 (HER3)
TW201601753A (en) * 2013-09-30 2016-01-16 第一三共股份有限公司 Protein biomarker and uses thereof
US20150152508A1 (en) * 2013-09-30 2015-06-04 Daiichi Sankyo Company, Limited Nucleic acid biomarker and use thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
KR20170137886A (en) * 2015-04-17 2017-12-13 메리맥 파마슈티컬즈, 인크. Therapeutic combination therapy
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP2019508428A (en) 2016-03-15 2019-03-28 メリマック ファーマシューティカルズ インコーポレーティッド Methods for treating ER +, HER2-, HRG + breast cancer using combination therapy comprising an anti-ERBB3 antibody
CN111647074B (en) * 2020-06-01 2023-12-19 皖南医学院 HER3 dimerization interface antigen peptide, recombinant antigen peptide, encoding gene and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117815A1 (en) * 2005-11-04 2007-05-24 James Pluda Method of treating cancers with SAHA and pemetrexed
US20090082295A1 (en) * 2005-11-11 2009-03-26 Pfizer Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
US20090214562A1 (en) * 2005-05-03 2009-08-27 Karel Steven J Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20100056761A1 (en) * 2007-02-16 2010-03-04 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US20110027291A1 (en) * 2008-08-15 2011-02-03 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
US20110189092A1 (en) * 2009-03-30 2011-08-04 Scott Eliasof Polymer-agent conjugates, particles, compositions, and related methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090214562A1 (en) * 2005-05-03 2009-08-27 Karel Steven J Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20070117815A1 (en) * 2005-11-04 2007-05-24 James Pluda Method of treating cancers with SAHA and pemetrexed
US20090082295A1 (en) * 2005-11-11 2009-03-26 Pfizer Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
US20100056761A1 (en) * 2007-02-16 2010-03-04 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US7846440B2 (en) * 2007-02-16 2010-12-07 Merrimack Pharmaceuticals, Inc. Antibodies against ErbB3 and uses thereof
US20110027291A1 (en) * 2008-08-15 2011-02-03 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
US20110189092A1 (en) * 2009-03-30 2011-08-04 Scott Eliasof Polymer-agent conjugates, particles, compositions, and related methods of use

Also Published As

Publication number Publication date
WO2013023043A2 (en) 2013-02-14
AU2012294326A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
WO2013023043A3 (en) Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
IL291613A (en) Inhibitory anti-factor xii/fxiia monoclonal antibodies, method of producing the same, pharmaceutical composition containing the same and medical uses
WO2012162561A3 (en) Multivalent and monovalent multispecific complexes and their uses
IL257330B (en) Compositions, methods and kits for diagnosis of lung cancer
MX2019008065A (en) Compositions comprising anti-cd38 antibodies and lenalidomide.
EP2714081A4 (en) Methods, compositions, and kits for the treatment of cancer
PH12014501108A1 (en) Anti-il-36r antibodies
WO2014018563A3 (en) Methods for the treatment of cancer
WO2014144600A3 (en) Multivalent and monovalent multispecific complexes and their uses
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
PH12014502406A1 (en) Anti-il-23p19 antibodies
WO2011123489A3 (en) Anti-cd40 antibodies
MY162791A (en) Anti-il-23 antibodies
EP2825669A4 (en) Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
WO2012103028A3 (en) Methods and compositions for preparing noribogaine from voacangine
WO2013023015A3 (en) Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2012135047A3 (en) Methods and compositions for preparing noribogaine from voacangine
WO2012107416A3 (en) Improved immunotherapy
WO2010151541A8 (en) Polymorphic form d of bazedoxifene acetate and methods of preparing same
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
WO2012177935A8 (en) Compositions and methods for the treatment of cancer
WO2013173759A3 (en) Macrocyclic nucleoside phosphoramidate derivatives
WO2015023504A8 (en) Methods for reducing exacerbation rates of asthma using benralizumab

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2012294326

Country of ref document: AU

Date of ref document: 20120809

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12822371

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12822371

Country of ref document: EP

Kind code of ref document: A2